Opportunity To Co-Sponsor Office of Research Integrity Events, 64067-64068 [2022-22887]
Download as PDF
<![CDATA[
64067
Federal Register / Vol. 87, No. 203 / Friday, October 21, 2022 / Notices
comments from OVC grant recipients
during this public comment period.
Need and Proposed Use of the
Information: The information collected
on OVC grant recipient activities and
performance will help HRSA
demonstrate, adapt, assess, and
disseminate promising practices,
strategies, and novel models of virtual
care across the nation’s health centers.
The information will support an
assessment that yields:
• Increased evidence of how to
optimize the use of virtual care in the
Health Center Program to enhance
access to care and improve clinical
quality for underserved communities
and special and vulnerable populations.
• Maximized impact of the new OVC
grant program, as a model to be adapted,
leveraged, and scaled across other
HRSA funding opportunities.
• Enhanced evidence base for
recommendations to promote and scale
virtual care innovations focused on
increasing health equity specific to
Health Center Program patients.
The assessment will include
descriptive analyses of the data on grant
recipient activities and performance,
including analyses of trends over time.
The analyses will inform
recommendations for performance
measures that HRSA could scale across
the Health Center Program and across
other grant programs like the OVC grant
program.
The grant recipient activities related
to implementation of novel models of
virtual care, including aggregate data on
patients served and the services they
received, will be captured via monthly
progress reports. A set of health center
performance measures will be captured
in a bi-annual progress report and will
provide insight into health equity and
virtual care. Grant recipients will collect
and report performance measures based
on project goals and objectives that span
four key population health and clinical
domain areas, including (1) Increased
Access to Care and Information; (2)
Improve Clinical Quality and Health
Outcomes; (3) Enhance Patient Care
Coordination; and (4) Promote Health
Equity.
Based on comments from OVC grant
recipients, the average hours of burden
per response for the biannual progress
report has increased to 55.9 hours from
48 hours as proposed in the 60-day
Federal Register Notice. This new
burden estimate accounts for the fact
that performance measures in the
biannual progress report have different
levels of burden per response. For
example, some measures required
significant workflow changes or had
more complexity. In addition, both the
biannual and monthly progress reports
were revised to include updated terms
and definitions based on feedback
collected from OVC grant recipients
during the public comment period.
Likely Respondents: Respondents will
be the 29 health centers that received
supplemental awards through the OVC
grant program.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Form name
Total
responses
Average
burden per
response
(in hours)
Total burden
hours
OVC Grant Monthly Progress Report ..................................
OVC Grant Bi-Annual Progress Report ...............................
29
29
12
2
348
58
2.0
55.9
696.0
3,242.2
Total ..............................................................................
29
........................
406
........................
3,938.2
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Maria G. Button,
Director, Executive Secretariat.
jspears on DSK121TN23PROD with NOTICES
Number of
responses per
respondent
[FR Doc. 2022–22868 Filed 10–20–22; 8:45 am]
BILLING CODE 4165–15–P
VerDate Sep<11>2014
19:08 Oct 20, 2022
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Opportunity To Co-Sponsor Office of
Research Integrity Events
AGENCY:
ACTION:
Office of the Secretary, HHS.
Notice.
The Office of Research
Integrity (ORI) announces the
opportunity for non-federal public and
private sector entities to co-sponsor ORI
conferences, workshops, symposia,
meetings, roundtables, or other such
events (collectively, ‘‘Events’’). ORI cosponsors a limited number of events
with non-federal entities each year.
Potential co-sponsors must have
demonstrated interest and experience in
the responsible conduct of research or
SUMMARY:
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
handling allegations of research
misconduct. Potential co-sponsors must
be willing to participate substantively in
the co-sponsored event.
DATES: Expressions of interest for cosponsorship of an ORI Event may be
submitted on an ongoing basis
throughout the fiscal year (October 1,
2022–September 30, 2023) or beyond.
ADDRESSES: Expressions of interest for
co-sponsorship of an ORI Event should
be sent by email to AskORI@HHS.GOV
with ‘‘Co-sponsorship for ORI Event’’ in
the subject field.
FOR FURTHER INFORMATION CONTACT:
Tracey Randolph, Program Analyst,
Office of Research Integrity, 1101
Wootton Parkway, Suite 240,
Rockville, MD 20852, (240) 453–8200
SUPPLEMENTARY INFORMATION: ORI
oversees and directs U.S. Public Health
Service (PHS) research integrity
E:\FR\FM\21OCN1.SGM
21OCN1
jspears on DSK121TN23PROD with NOTICES
64068
Federal Register / Vol. 87, No. 203 / Friday, October 21, 2022 / Notices
activities on behalf of the Secretary of
the U.S. Department of Health and
Human Services (HHS), with the
exception of the regulatory research
integrity activities of the Food and Drug
Administration. ORI is a program office
within the Office of the Assistant
Secretary for Health, Office of the
Secretary, HHS.
Core to ORI’s mission is the support
of education and outreach activities that
aid PHS-funded research institutions in
their efforts ‘‘to teach the responsible
conduct of research, promote research
integrity, prevent research misconduct,
and . . . to respond effectively to
allegations of research misconduct’’ (65
FR 30600, 30601 (May 12, 2000)). ORI
Events contribute to this mission by
providing education, training, and/or
the opportunity for discussion related to
topics such as handling allegations of
research misconduct and fostering
research integrity and the responsible
conduct of research. ORI Events
typically are moderately sized, usually
accepting between 20 and 150
attendees, and convened in person or
virtually for one to three days.
Co-sponsors will work with ORI staff
to jointly develop an event. Both ORI
and the co-sponsor must contribute
substantively to the development of the
event. Co-sponsors can charge
registration fees to recover costs
associated with the events; however, cosponsors may not set registration fees at
an amount higher than necessary to
recover event-related expenses. Further,
co-sponsors are solely responsible for
collecting and handling any registration
fees.
Eligibility for Co-Sponsorship: The cosponsoring entity must have
demonstrated interest and experience in
fostering the responsible conduct of
research or handling of research
misconduct allegations. The cosponsoring entity must participate
substantively in the co-sponsored
activity, and not just provide funding,
logistical services, or other material
support.
Expression of Interest in CoSponsorship: An entity shall provide an
expression of interest that includes (1)
one to two paragraphs detailing why
ORI should select the entity, including
the entity’s leadership in and
management of matters involving
research integrity and the responsible
conduct of research, and (2) a bulleted
outline addressing the seven topics
listed below. The expression of interest
should be one to two pages in length,
single-spaced, and at least 11-point font.
An entity may submit an expression of
interest individually or jointly with
other entities describing their relative
VerDate Sep<11>2014
19:08 Oct 20, 2022
Jkt 259001
contributions. The seven topics to be
addressed in the outline are:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
1. The entity’s interest and goals in
promoting research integrity and/or
the responsible conduct of research
2. The entity’s prior experience and
current readiness to undertake the
responsibilities described above
3. The type of event(s) that the entity is
interested in co-sponsoring with ORI
4. Facilities available for the event(s),
including the distance from the
facilities to a major airport
5. Any current constraints with respect
to dates or facilities
6. Whether the entity has co-sponsored
an ORI Event in the past 36 months
7. Whether the entity has any cases,
allegations, or other related matters
pending with ORI
National Institutes of Health
Evaluation Criteria: After engaging in
exploratory discussions with potential
co-sponsors who respond to this notice,
HHS will apply the following
considerations, as appropriate and
relevant, to select the co-sponsor(s):
• Qualifications and capability to fulfill
co-sponsorship responsibilities
• Suitability of the location of the
proposed event in terms of the overall
geographical distribution of recent or
planned ORI Events
• Potential for reaching, generating, and
engaging an adequate number of
attendees
• Availability and description of
facilities needed to support the event
• Availability of administrative support
for the logistics of hosting such events
The duties of the co-sponsor will be
outlined in a co-sponsorship agreement
with ORI that will set forth the details
of the co-sponsored event, including the
requirements that any fees collected by
the co-sponsor shall be limited to the
amount necessary to cover the cosponsor’s event-related expenses. This
co-sponsorship agreement does not
represent an endorsement by ORI of an
individual co-sponsor’s policies,
positions, or activities.
Dated: October 13, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.
[FR Doc. 2022–22887 Filed 10–20–22; 8:45 am]
BILLING CODE 4150–31–P
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
Proposed Collection; 60-Day Comment
Request, National Institute on Drug
Abuse (NIDA) Summer Research
Internship Program
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
In compliance with the
requirement of the Paperwork
Reduction Act of 1995 to provide
opportunity for public comment on
proposed data collection projects, the
National Institute on Drug Abuse
(NIDA) will publish periodic summaries
of proposed projects to be submitted to
the Office of Management and Budget
(OMB) for review and approval.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 60 days of the date of this
publication.
SUMMARY:
To
obtain a copy of the data collection
plans and instruments, submit
comments in writing, or request more
information on the proposed project,
contact: Dr. Wilson Compton, Acting
Director, Office of Research Training,
Diversity, and Disparities, National
Institute on Drug Abuse, 3WFN, 11601
Landsdown St., Room 09D18, North
Bethesda, Maryland, 20892 or call nontoll-free number (301) 443–6480 or
Email your request, including your
address, to: Wilson.Compton@nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
FOR FURTHER INFORMATION CONTACT:
Section
3506(c)(2)(A) of the Paperwork
Reduction Act of 1995 requires written
comments and/or suggestions from the
public and affected agencies are invited
to address one or more of the following
points: (1) Whether the proposed
collection of information is necessary
for the proper performance of the
function of the agency, including
whether the information will have
practical utility; (2) The accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used; (3)
Ways to enhance the quality, utility, and
clarity of the information to be
collected; and (4) Ways to minimizes
the burden of the collection of
information on those who are to
respond, including the use of
SUPPLEMENTARY INFORMATION:
E:\FR\FM\21OCN1.SGM
21OCN1
]]>Agencies
[Federal Register Volume 87, Number 203 (Friday, October 21, 2022)]
[Notices]
[Pages 64067-64068]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-22887]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Opportunity To Co-Sponsor Office of Research Integrity Events
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Office of Research Integrity (ORI) announces the
opportunity for non-federal public and private sector entities to co-
sponsor ORI conferences, workshops, symposia, meetings, roundtables, or
other such events (collectively, ``Events''). ORI co-sponsors a limited
number of events with non-federal entities each year. Potential co-
sponsors must have demonstrated interest and experience in the
responsible conduct of research or handling allegations of research
misconduct. Potential co-sponsors must be willing to participate
substantively in the co-sponsored event.
DATES: Expressions of interest for co-sponsorship of an ORI Event may
be submitted on an ongoing basis throughout the fiscal year (October 1,
2022-September 30, 2023) or beyond.
ADDRESSES: Expressions of interest for co-sponsorship of an ORI Event
should be sent by email to [email protected] with ``Co-sponsorship for ORI
Event'' in the subject field.
FOR FURTHER INFORMATION CONTACT:
Tracey Randolph, Program Analyst, Office of Research Integrity, 1101
Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453-8200
SUPPLEMENTARY INFORMATION: ORI oversees and directs U.S. Public Health
Service (PHS) research integrity
[[Page 64068]]
activities on behalf of the Secretary of the U.S. Department of Health
and Human Services (HHS), with the exception of the regulatory research
integrity activities of the Food and Drug Administration. ORI is a
program office within the Office of the Assistant Secretary for Health,
Office of the Secretary, HHS.
Core to ORI's mission is the support of education and outreach
activities that aid PHS-funded research institutions in their efforts
``to teach the responsible conduct of research, promote research
integrity, prevent research misconduct, and . . . to respond
effectively to allegations of research misconduct'' (65 FR 30600, 30601
(May 12, 2000)). ORI Events contribute to this mission by providing
education, training, and/or the opportunity for discussion related to
topics such as handling allegations of research misconduct and
fostering research integrity and the responsible conduct of research.
ORI Events typically are moderately sized, usually accepting between 20
and 150 attendees, and convened in person or virtually for one to three
days.
Co-sponsors will work with ORI staff to jointly develop an event.
Both ORI and the co-sponsor must contribute substantively to the
development of the event. Co-sponsors can charge registration fees to
recover costs associated with the events; however, co-sponsors may not
set registration fees at an amount higher than necessary to recover
event-related expenses. Further, co-sponsors are solely responsible for
collecting and handling any registration fees.
Eligibility for Co-Sponsorship: The co-sponsoring entity must have
demonstrated interest and experience in fostering the responsible
conduct of research or handling of research misconduct allegations. The
co-sponsoring entity must participate substantively in the co-sponsored
activity, and not just provide funding, logistical services, or other
material support.
Expression of Interest in Co-Sponsorship: An entity shall provide
an expression of interest that includes (1) one to two paragraphs
detailing why ORI should select the entity, including the entity's
leadership in and management of matters involving research integrity
and the responsible conduct of research, and (2) a bulleted outline
addressing the seven topics listed below. The expression of interest
should be one to two pages in length, single-spaced, and at least 11-
point font. An entity may submit an expression of interest individually
or jointly with other entities describing their relative contributions.
The seven topics to be addressed in the outline are:
1. The entity's interest and goals in promoting research integrity and/
or the responsible conduct of research
2. The entity's prior experience and current readiness to undertake the
responsibilities described above
3. The type of event(s) that the entity is interested in co-sponsoring
with ORI
4. Facilities available for the event(s), including the distance from
the facilities to a major airport
5. Any current constraints with respect to dates or facilities
6. Whether the entity has co-sponsored an ORI Event in the past 36
months
7. Whether the entity has any cases, allegations, or other related
matters pending with ORI
Evaluation Criteria: After engaging in exploratory discussions with
potential co-sponsors who respond to this notice, HHS will apply the
following considerations, as appropriate and relevant, to select the
co-sponsor(s):
Qualifications and capability to fulfill co-sponsorship
responsibilities
Suitability of the location of the proposed event in terms of
the overall geographical distribution of recent or planned ORI Events
Potential for reaching, generating, and engaging an adequate
number of attendees
Availability and description of facilities needed to support
the event
Availability of administrative support for the logistics of
hosting such events
The duties of the co-sponsor will be outlined in a co-sponsorship
agreement with ORI that will set forth the details of the co-sponsored
event, including the requirements that any fees collected by the co-
sponsor shall be limited to the amount necessary to cover the co-
sponsor's event-related expenses. This co-sponsorship agreement does
not represent an endorsement by ORI of an individual co-sponsor's
policies, positions, or activities.
Dated: October 13, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity, Office of the Assistant
Secretary for Health.
[FR Doc. 2022-22887 Filed 10-20-22; 8:45 am]
BILLING CODE 4150-31-P
